{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:39:41Z","timestamp":1772627981472,"version":"3.50.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012139","name":"NHS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1053\/j.seminoncol.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T17:11:56Z","timestamp":1560877916000},"page":"145-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma"],"prefix":"10.1053","volume":"46","author":[{"given":"Anne","family":"Tsao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio V.","family":"Scagliotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.seminoncol.2019.06.001_bib0001","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0002","unstructured":"Mesothelioma statistics and facts. Copyright \u00a9 2018 by the Mesothelioma Cancer Alliance at Mesothelioma.com. https:\/\/www.mesothelioma.com\/mesothelioma\/statistics\/."},{"issue":"4","key":"10.1053\/j.seminoncol.2019.06.001_bib0003","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"issue":"8","key":"10.1053\/j.seminoncol.2019.06.001_bib0004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1053\/j.seminoncol.2019.06.001_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/ijerph15030531","article-title":"Trends and the economic effect of asbestos bans and decline in asbestos consumption and production worldwide","volume":"15","author":"Allen","year":"2018","journal-title":"Int J Environ Res Public Health"},{"issue":"suppl_5","key":"10.1053\/j.seminoncol.2019.06.001_bib0006","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2019.06.001_bib0007","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0008","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev-publhealth-031811-124704","article-title":"The worldwide pandemic of asbestos-related diseases","volume":"34","author":"Stayner","year":"2013","journal-title":"Annu Rev Public Health"},{"issue":"142","key":"10.1053\/j.seminoncol.2019.06.001_bib0009","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"14","key":"10.1053\/j.seminoncol.2019.06.001_bib0010","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2019.06.001_bib0011","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: results of the international expanded access program","volume":"3","author":"Santoro","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1053\/j.seminoncol.2019.06.001_bib0012","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2019.06.001_bib0013","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2019.06.001_bib0014","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/j.jtho.2016.11.302","article-title":"OA13.03 Long-term overall survival for patients with malignant pleural mesothelioma on pembrolizumab enrolled in KEYNOTE-028","volume":"12","author":"Alley","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1053\/j.seminoncol.2019.06.001_bib0015","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl_5","key":"10.1053\/j.seminoncol.2019.06.001_bib0016","article-title":"LBA58_PR second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial","volume":"28","author":"Zalcman","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2019.06.001_bib0017","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminoncol.2019.06.001_bib0018","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2019.06.001_bib0019","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2019.06.001_bib0020","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/j.jtho.2016.11.301","article-title":"OA13.02 phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis","volume":"12","author":"Kindler","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0021a","unstructured":"National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Malignant Pleural Mesothelioma V.2.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed [April 1, 2019]. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0022","unstructured":"Nakano T, Okada M, Kijima T, et al. Long-term efficacy and safety of nivolumab in second- or third-line Japanese malignant pleural mesothelioma patients (phase II: MERIT study). Abstract OA08.03. Presented at IASLC 2018, September 23-26, 2018, Toronto, Canada. Available at:https:\/\/s3.amazonaws.com\/iaslc\/pdf\/WCLC2018-Abstract-Book_Web.pdf."},{"issue":"27","key":"10.1053\/j.seminoncol.2019.06.001_bib0023","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.2174\/092986710791959710","article-title":"Will antiangiogenic agents be a future for mesothelioma therapy?","volume":"17","author":"Belli","year":"2010","journal-title":"Curr Med Chem"},{"issue":"5","key":"10.1053\/j.seminoncol.2019.06.001_bib0024","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2019.06.001_bib0025","first-page":"49","article-title":"Platelet-derived growth factor signaling and human cancer","volume":"36","author":"Yu","year":"2003","journal-title":"J Biochem Mol Biol"},{"issue":"19","key":"10.1053\/j.seminoncol.2019.06.001_bib0026","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1158\/1078-0432.CCR-11-0659","article-title":"Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis","volume":"17","author":"Lieu","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2019.06.001_bib0027","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","article-title":"Angiogenesis is an independent prognostic factor in malignant mesothelioma","volume":"85","author":"Edwards","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2019.06.001_bib0028","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/JTO.0b013e3181d2f008","article-title":"Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma","volume":"5","author":"Yasumitsu","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2019.06.001_bib0029","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ajpath.2011.05.060","article-title":"Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network","volume":"179","author":"Li","year":"2011","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1053\/j.seminoncol.2019.06.001_bib0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0","article-title":"Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression","volume":"189","author":"Kumar-Singh","year":"1999","journal-title":"J Pathol"},{"issue":"7","key":"10.1053\/j.seminoncol.2019.06.001_bib0031","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1158\/1535-7163.MCT-07-0052","article-title":"Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion","volume":"6","author":"Tsao","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1053\/j.seminoncol.2019.06.001_bib0032","doi-asserted-by":"crossref","first-page":"198","DOI":"10.18632\/oncotarget.126","article-title":"Src activates Abl to augment Robo1 expression in order to promote tumor cell migration","volume":"1","author":"Khusial","year":"2010","journal-title":"Oncotarget"},{"issue":"5","key":"10.1053\/j.seminoncol.2019.06.001_bib0033","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/onc.2016.226","article-title":"Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells","volume":"36","author":"Eguchi","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1053\/j.seminoncol.2019.06.001_bib0034","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/ijms19010299","article-title":"\"Vessels in the storm\": searching for prognostic and predictive angiogenic factors in colorectal cancer","volume":"19","author":"Angelucci","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1053\/j.seminoncol.2019.06.001_bib0035","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/01.RES.0000218275.54089.12","article-title":"Signaling and functions of angiopoietin-1 in vascular protection","volume":"98","author":"Brindle","year":"2006","journal-title":"Circ Res"},{"issue":"5","key":"10.1053\/j.seminoncol.2019.06.001_bib0036","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1183\/09031936.00154009","article-title":"A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma","volume":"36","author":"Tabata","year":"2010","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1053\/j.seminoncol.2019.06.001_bib0037","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2017.62","article-title":"First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0038","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.2741\/2787","article-title":"The role of CD26\/dipeptidyl peptidase IV in cancer","volume":"13","author":"Havre","year":"2008","journal-title":"Front Biosci"},{"issue":"6","key":"10.1053\/j.seminoncol.2019.06.001_bib0039","first-page":"1369","article-title":"Overexpression of CD26\/DPPIV in mesothelioma tissue and mesothelioma cell lines","volume":"26","author":"Amatya","year":"2011","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1053\/j.seminoncol.2019.06.001_bib0040","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1158\/1078-0432.CCR-11-1990","article-title":"CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma","volume":"18","author":"Aoe","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2019.06.001_bib0041","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1253\/circj.CJ-16-1326","article-title":"Dipeptidyl peptidase-IV inhibition for the treatment of cardiovascular disease\u2014recent insights focusing on angiogenesis and neovascularization","volume":"81","author":"Lei","year":"2017","journal-title":"Circ J"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0042","unstructured":"Genentech Inc. Prescribing information for avastin (bevacizumab). 2017. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125085s319lbl.pdf[Accessed April 2019]."},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0043","unstructured":"Genentech I. Summary of product characteristics for avastin (bevacizumab). 2017. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000582\/WC500029271.pdf[Accessed April 2019]."},{"issue":"20","key":"10.1053\/j.seminoncol.2019.06.001_bib0044","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","article-title":"Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma","volume":"30","author":"Kindler","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2019.06.001_bib0045","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/bjc.2013.368","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma","volume":"109","author":"Ceresoli","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1053\/j.seminoncol.2019.06.001_bib0046","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","article-title":"A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma","volume":"77","author":"Dowell","year":"2012","journal-title":"Lung Cancer"},{"issue":"10026","key":"10.1053\/j.seminoncol.2019.06.001_bib0047","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.seminoncol.2019.06.001_bib0048","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.seminoncol.2019.06.001_bib0049","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cllc.2017.03.010","article-title":"LUME-Meso: design and rationale of the phase III part of a placebo-controlled study of nintedanib and pemetrexed\/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma","volume":"18","author":"Scagliotti","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0050","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Prescribing information for OFEV (nintedanib). 2018. Available from:https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Ofev\/ofev.pdf[Accessed April 2019]."},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0051","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Summary of product characteristics for vargatef (nintedanib). 2018. Available from:https:\/\/www.medicines.org.uk\/emc\/medicine\/29790[Accessed April 2019]."},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0052","unstructured":"Boehringer Ingelheim International GmbH.Summary of product characteristics for OFEV (nintedanib) Available from:https:\/\/www.ema.europa.eu\/documents\/product-information\/ofev-epar-product-information_en.pdf [Accessed April 2019]."},{"issue":"15","key":"10.1053\/j.seminoncol.2019.06.001_bib0053","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1158\/1078-0432.CCR-17-1507","article-title":"Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo","volume":"24","author":"Laszlo","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0054","series-title":"Astract PP02.61. Presented at the 13th International Conference on Malignant Lymphoma, June 17\u201020","article-title":"Preclinical investigation of the therapeutic potential of nintedanib in malignant pleural mesothelioma","author":"Laszlo","year":"2015"},{"issue":"31","key":"10.1053\/j.seminoncol.2019.06.001_bib0055","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: phase II results from the randomized, placebo-controlled LUME-Meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1053\/j.seminoncol.2019.06.001_bib0056","first-page":"1618PD","article-title":"1618PD overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N)\u202f+\u202fpemetrexed\/cisplatin (PEM\/CIS) vs placebo (P)\u202f+\u202fPEM\/CIS in chemo-na\u00efve patients (pts) with malignant pleural mesothelioma (MPM)","volume":"28","author":"Novello","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2019.06.001_bib0057","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1053\/j.seminoncol.2019.06.001_bib0058","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdv286","article-title":"A phase I\/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients","volume":"26","author":"Van Cutsem","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2019.06.001_bib0059","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0060","doi-asserted-by":"crossref","unstructured":"Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib\u202f+\u202fpemetrexed\/cisplatin in patients with unresectable MPM: phase III results from the LUME-Meso trial. Oral presentation. Presented at IASLC 19th World Conference on Lung Cancer; 2018 Sep 23\u201326; Toronto, Canada. PL02.09","DOI":"10.1016\/j.jtho.2018.08.014"},{"issue":"8","key":"10.1053\/j.seminoncol.2019.06.001_bib0061","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jtho.2017.05.021","article-title":"Phase I trial of cediranib in combination with cisplatin and pemetrexed in chemonaive patients with unresectable malignant pleural mesothelioma (SWOG S0905)","volume":"12","author":"Tsao","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"15_suppl","key":"10.1053\/j.seminoncol.2019.06.001_bib0062","doi-asserted-by":"crossref","first-page":"8514","DOI":"10.1200\/JCO.2018.36.15_suppl.8514","article-title":"SWOG S0905: a randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma","volume":"36","author":"Tsao","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2019.06.001_bib0063","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cllc.2013.12.008","article-title":"Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma","volume":"15","author":"Tsao","year":"2014","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"10.1053\/j.seminoncol.2019.06.001_bib0064","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtho.2016.01.014","article-title":"A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: a single-center trial combining clinical and translational outcomes","volume":"11","author":"Buikhuisen","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"22","key":"10.1053\/j.seminoncol.2019.06.001_bib0065","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1053\/j.seminoncol.2019.06.001_bib0066","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminoncol.2019.06.001_bib0067","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2019.06.001_bib0068","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1053\/j.seminoncol.2019.06.001_bib0069","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.4049\/jimmunol.1303116","article-title":"CD47 signaling regulates the immunosuppressive activity of VEGF in T cells","volume":"193","author":"Kaur","year":"2014","journal-title":"J Immunol"},{"issue":"1","key":"10.1053\/j.seminoncol.2019.06.001_bib0070","doi-asserted-by":"crossref","first-page":"S813","DOI":"10.1016\/j.jtho.2016.11.1097","article-title":"P2.01-045 nintedanib improves anti-tumor efficacy in combination with anti PD-1 in syngeneic tumor models sensitive and refractory to IO inhibition","volume":"12","author":"Hilberg","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"suppl; abstr 9002","key":"10.1053\/j.seminoncol.2019.06.001_bib0071","article-title":"Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo)\u202f+\u202fchemotherapy (chemo) \u00b1 bevacizumab (bev) vs chemo\u202f+\u202fbev in 1L nonsquamous (NSQ) NSCLC","volume":"36","author":"Socinski","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminoncol.2019.06.001_bib0072","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2019.06.001_bib0073","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma","volume":"6","author":"Laurie","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2019.06.001_bib0074","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2019.06.001_bib0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago phase II consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1053\/j.seminoncol.2019.06.001_bib0076","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of cancer and leukemia group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2019.06.001_bib0077","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2019.06.001_bib0078","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.12.004","article-title":"A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: the Ontario clinical oncology group","volume":"104","author":"Laurie","year":"2017","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1053\/j.seminoncol.2019.06.001_bib0079","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.lungcan.2004.10.005","article-title":"Thalidomide in patients with malignant pleural mesothelioma","volume":"48","author":"Baas","year":"2005","journal-title":"Lung Cancer"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775419300600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775419300600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:54:52Z","timestamp":1758804892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775419300600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0093775419300600"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2019.06.001","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}